Phase
Condition
Acute Pain
Pain
Treatment
Paracetamol 500 Mg Oral Tablet X2
Nefopam HCl 30 MG Oral Tablet X2
nefopam hydrochloride 30mg / paracetamol 500mg X2
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Main Inclusion Criteria:
Male and female patient aged from 18 years up to 65 years,
Patient scheduled to undergo the surgical removal of at least one fully or partiallyimpacted third mandibular molar requiring bone removal under short-acting localanaesthetic (mepivacaine or lidocaine) with or without vasoconstrictor,
Patient weighing > 50 kg,
Patient who has signed a written informed consent prior to any study-relatedprocedures.
Additional inclusion criteria after surgery (randomization):
Patient experiencing moderate to severe pain within 4 hours after the dentalextraction, defined by a baseline pain intensity Visual Analogic Scale (VAS) score ≥ 50 mm,
Third molar extraction(s) completed without any immediate complication, that in theopinion of the investigator, would interfere with the study conduct and/orassessments (e.g., suspected neurosensory complication, incomplete removal of tooth)
Exclusion
Main Exclusion Criteria:
Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs)within 3 days preceding the day of randomization or within 5 times the eliminationhalf-life whichever the longest,
Woman with positive results on a urine pregnancy test or breastfeeding woman orwoman of childbearing potential without an effective contraception,
Patient with a history of convulsive disorders,
Patient taking mono-amine-oxidase (MAO) inhibitors (including but not limited toselegiline, isocarboxazid, tranylcypromine, phenelzine...),
Patient with an abnormal cardiac condition: medically significant disorders ofcardiac rate and/or rhythm,
Patient with known anaemia,
Patient with known pulmonary disease,
Patient with known active gastric or duodenal ulcer or a history of recurrentgastrointestinal ulcer/bleeding,
Patient with known glaucoma,
Patients with a prostatic hyperplasia or urinary retention,
Patient with current or chronic history of liver disease, or known hepatic orbiliary abnormalities,
Patient with a current or chronic history of severe renal impairment (glomerularfiltration below 30 mL/min),
Study Design
Connect with a study center
Hôpital Erasme- ULB- Bruxelles
Bruxelles,
BelgiumSite Not Available
Hôpital Leuven
Leuven,
BelgiumSite Not Available
CH Amiens
Amiens, 80054
FranceSite Not Available
CHU Angers
Angers, 49933
FranceSite Not Available
Ch Boulogne
Boulogne,
FranceSite Not Available
CHU Marseille
Marseille, 13385
FranceSite Not Available
Centre Hospitalier de Pontoise
Pontoise, 95300
FranceSite Not Available
HIA Toulon
Toulon, 83800
FranceSite Not Available
CHU de tours
Tours, 37170
FranceSite Not Available
Clinexpert Kft.
Budapest,
HungarySite Not Available
Óbudai Egészségügyi Centrum
Budapest,
HungarySite Not Available
Swan-Med Kft.
Letavertes,
HungarySite Not Available
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház,
Nyíregyháza,
HungarySite Not Available
SmileDent Kft.
Szeged,
HungarySite Not Available
Szent Borbála Kórház,
Tatabánya,
HungarySite Not Available
Óbudai Egészségügyi Centrum
Zalaegerszeg,
HungarySite Not Available
LLC Center for interdisciplinary dentistry & neuro
Moscow, 141207
Russian FederationSite Not Available
State Medico-stomato Univ., by A.I. Evdokimov
Moscow,
Russian FederationSite Not Available
Regional clinical hospital
Yaroslavl, 150062
Russian FederationSite Not Available
Birmingham School of Dentistry
Birmingham, B5 7EG
United KingdomSite Not Available
University Dental Hospital
Cardiff, CF14 4XY
United KingdomSite Not Available
Edinburgh Dental Institute
Edinburgh, EH3 9HX
United KingdomSite Not Available
BARTS HEALTH NHS TRUST Royal London Hospital
London, E1 1FR
United KingdomSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.